RxDoctor Payments Data

Melissa Payne, NP

Family · Williamsville, NYNPI 1124282884

Payments from drug & device makers

$12,930in general payments, 2019–2025

Across 715 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$820
  • Amgen$769
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$12,914100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,930 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$16,008
Medicare patients
96
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$60,362
EliquisApixaban31$26,118
FarxigaDapagliflozin Propanediol16$25,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$21,586
InvokanaCanagliflozin14$19,748
OzempicSemaglutide19$17,198
TrulicityDulaglutide13$12,214
LinzessLinaclotide12$10,380
Tresiba Flextouch U-200Insulin Degludec12$8,678
Levothyroxine Sodium261$4,513
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,977
SymbicortBudesonide/Formoterol Fumarate12$2,847
Rosuvastatin Calcium136$2,215
Albuterol Sulfate HfaAlbuterol Sulfate59$2,165
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,996

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,047$60,36258 claims
AstraZenecaFarxiga, Symbicort$820$28,60728 claims
PfizerEliquis$385$26,11831 claims
GSKTrelegy Ellipta$1,225$21,58634 claims
Johnson & JohnsonInvokana$405$19,74814 claims
Novo NordiskOzempic$360$17,19819 claims
Lilly USA, LLCTrulicity$1,272$12,21413 claims
AbbVieLinzess$1,804$10,38012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →